These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29089038)

  • 1. The impact of N-acetylcysteine and ascorbic acid in contrast-induced nephropathy in critical care patients: an open-label randomized controlled study.
    Palli E; Makris D; Papanikolaou J; Garoufalis G; Tsilioni I; Zygoulis P; Zakynthinos E
    Crit Care; 2017 Oct; 21(1):269. PubMed ID: 29089038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial.
    Brueck M; Cengiz H; Hoeltgen R; Wieczorek M; Boedeker RH; Scheibelhut C; Boening A
    J Invasive Cardiol; 2013 Jun; 25(6):276-83. PubMed ID: 23735352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-Induced nephropathy: a prospective randomized study.
    Albabtain MA; Almasood A; Alshurafah H; Alamri H; Tamim H
    J Interv Cardiol; 2013 Feb; 26(1):90-6. PubMed ID: 22994682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do intravenous N-acetylcysteine and sodium bicarbonate prevent high osmolal contrast-induced acute kidney injury? A randomized controlled trial.
    Inda-Filho AJ; Caixeta A; Manggini M; Schor N
    PLoS One; 2014; 9(9):e107602. PubMed ID: 25254489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study.
    Huber W; Eckel F; Hennig M; Rosenbrock H; Wacker A; Saur D; Sennefelder A; Hennico R; Schenk C; Meining A; Schmelz R; Fritsch R; Weiss W; Hamar P; Heemann U; Schmid RM
    Radiology; 2006 Jun; 239(3):793-804. PubMed ID: 16714461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-acetylcysteine does not prevent contrast nephropathy in patients with renal impairment undergoing emergency CT: a randomized study.
    Poletti PA; Platon A; De Seigneux S; Dupuis-Lozeron E; Sarasin F; Becker CD; Perneger T; Saudan P; Martin PY
    BMC Nephrol; 2013 Jun; 14():119. PubMed ID: 23731573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
    Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention.
    Awal A; Ahsan SA; Siddique MA; Banerjee S; Hasan MI; Zaman SM; Arzu J; Subedi B
    Mymensingh Med J; 2011 Apr; 20(2):264-9. PubMed ID: 21522098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-acetylcysteine plus intravenous fluids versus intravenous fluids alone to prevent contrast-induced nephropathy in emergency computed tomography.
    Traub SJ; Mitchell AM; Jones AE; Tang A; O'Connor J; Nelson T; Kellum J; Shapiro NI
    Ann Emerg Med; 2013 Nov; 62(5):511-520.e25. PubMed ID: 23769807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-acetylcysteine versus ascorbic acid or N-acetylcysteine plus ascorbic acid in preventing contrast-induced nephropathy: A meta-analysis.
    Feng Y; Huang X; Li L; Chen Z
    Nephrology (Carlton); 2018 Jun; 23(6):530-538. PubMed ID: 28452187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of contrast-induced nephropathy with ascorbic acid.
    Zhou L; Chen H
    Intern Med; 2012; 51(6):531-5. PubMed ID: 22449658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.
    Kelly AM; Dwamena B; Cronin P; Bernstein SJ; Carlos RC
    Ann Intern Med; 2008 Feb; 148(4):284-94. PubMed ID: 18283206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of short-term infusion regimens of N-acetylcysteine plus intravenous fluids, sodium bicarbonate plus intravenous fluids, and intravenous fluids alone for prevention of contrast-induced nephropathy in the emergency department.
    Kama A; Yılmaz S; Yaka E; Dervişoğlu E; Doğan NÖ; Erimşah E; Pekdemir M
    Acad Emerg Med; 2014 Jun; 21(6):615-22. PubMed ID: 25039544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
    Habib M; Hillis A; Hammad A
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial.
    Fung JW; Szeto CC; Chan WW; Kum LC; Chan AK; Wong JT; Wu EB; Yip GW; Chan JY; Yu CM; Woo KS; Sanderson JE
    Am J Kidney Dis; 2004 May; 43(5):801-8. PubMed ID: 15112170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity.
    Poletti PA; Saudan P; Platon A; Mermillod B; Sautter AM; Vermeulen B; Sarasin FP; Becker CD; Martin PY
    AJR Am J Roentgenol; 2007 Sep; 189(3):687-92. PubMed ID: 17715118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of contrast-induced nephropathy by N-acetylcysteine in critically ill patients: different definitions, different results.
    Chousterman BG; Bouadma L; Moutereau S; Loric S; Alvarez-Gonzalez A; Mekontso-Dessap A; Laissy JP; Rahmouni A; Katsahian S; Brochard L; Schortgen F
    J Crit Care; 2013 Oct; 28(5):701-9. PubMed ID: 23683568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial.
    Kay J; Chow WH; Chan TM; Lo SK; Kwok OH; Yip A; Fan K; Lee CH; Lam WF
    JAMA; 2003 Feb; 289(5):553-8. PubMed ID: 12578487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.
    Spargias K; Alexopoulos E; Kyrzopoulos S; Iokovis P; Greenwood DC; Manginas A; Voudris V; Pavlides G; Buller CE; Kremastinos D; Cokkinos DV
    Circulation; 2004 Nov; 110(18):2837-42. PubMed ID: 15492300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.
    Boccalandro F; Amhad M; Smalling RW; Sdringola S
    Catheter Cardiovasc Interv; 2003 Mar; 58(3):336-41. PubMed ID: 12594698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.